| Item Type | Name |
|
Concept
|
Interferon-alpha
|
|
Concept
|
Receptor, Interferon alpha-beta
|
|
Academic Article
|
Interferon alfa-2a for melanoma metastases.
|
|
Academic Article
|
Does pegylated interferon alpha-2b confer additional benefit in the adjuvant treatment of high-risk melanoma?
|
|
Academic Article
|
Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.
|
|
Academic Article
|
Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.
|
|
Academic Article
|
Multiple antigen-engineered DC vaccines with or without IFNa to promote antitumor immunity in melanoma.
|
|
Academic Article
|
An update on adjuvant interferon for melanoma.
|
|
Academic Article
|
Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs.
|
|
Academic Article
|
Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data.
|
|
Academic Article
|
Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.
|
|
Academic Article
|
Sentinel lymph node biopsy and adjuvant therapy for melanoma: evidence revisited.
|
|
Academic Article
|
A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.
|
|
Academic Article
|
Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.
|
|
Academic Article
|
Adjuvant high-dose interferon-alpha therapy for high-risk melanoma.
|
|
Academic Article
|
Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
|
|
Academic Article
|
Fluorescence imaging analysis of upstream regulators and downstream targets of STAT3 in melanoma precursor lesions obtained from patients before and after systemic low-dose interferon-alpha treatment.
|
|
Academic Article
|
Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group.
|
|
Academic Article
|
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Building upon the standard of care in adjuvant therapy of high-risk melanoma.
|
|
Academic Article
|
Prognostic significance of autoimmunity during treatment of melanoma with interferon.
|
|
Academic Article
|
Response to "helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b".
|
|
Academic Article
|
Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b.
|
|
Academic Article
|
Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents.
|
|
Academic Article
|
Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.
|
|
Academic Article
|
Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.
|
|
Academic Article
|
Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma.
|
|
Academic Article
|
Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma.
|
|
Academic Article
|
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion.
|
|
Academic Article
|
STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy.
|
|
Academic Article
|
Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b.
|
|
Academic Article
|
Next generation of immunotherapy for melanoma.
|
|
Academic Article
|
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.
|
|
Academic Article
|
Effects of high-dose IFNalpha2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17.
|
|
Academic Article
|
Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696.
|
|
Academic Article
|
Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon.
|
|
Academic Article
|
Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials.
|
|
Academic Article
|
Clinical and immunologic basis of interferon therapy in melanoma.
|
|
Academic Article
|
Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients.
|
|
Academic Article
|
Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment.
|
|
Academic Article
|
Meeting report from the Third Global Workshop on Melanoma.
|
|
Academic Article
|
Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells.
|
|
Academic Article
|
Neoadjuvant therapy for high-risk bulky regional melanoma.
|
|
Academic Article
|
How much of a good thing? What duration for interferon alfa-2b adjuvant therapy?
|
|
Academic Article
|
IFN-a in the treatment of melanoma.
|
|
Academic Article
|
A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon.
|
|
Academic Article
|
Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-a or TLR-9 agonist and GM-CSF with peptide vaccination.
|
|
Academic Article
|
ECOG phase II trial of graded-dose peginterferon a-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602).
|
|
Academic Article
|
Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa.
|
|
Academic Article
|
Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.
|
|
Academic Article
|
Immune checkpoint blockade and interferon-a in melanoma.
|
|
Academic Article
|
Adjuvant Therapy of Melanoma.
|
|
Academic Article
|
BRAF Inhibitors and IFNa: Plus, Minus, or Indeterminate?
|
|
Academic Article
|
Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression.
|
|
Academic Article
|
Phase III Randomized Study of 4 Weeks of High-Dose Interferon-a-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).
|
|
Academic Article
|
Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-a2b in patients with metastatic melanoma.
|
|
Academic Article
|
High frequency of brain metastases after adjuvant therapy for high-risk melanoma.
|
|
Academic Article
|
Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690.
|
|
Academic Article
|
Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy.
|
|
Academic Article
|
Adjuvant interferon-a for the treatment of high-risk melanoma: An individual patient data meta-analysis.
|
|
Academic Article
|
Adjuvant Therapy in Resected Melanoma.
|
|
Academic Article
|
An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles.
|
|
Academic Article
|
Neoadjuvant ipilimumab (3?mg/kg or 10?mg/kg) and high dose IFN-a2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire.
|
|
Academic Article
|
E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-a2b in Advanced Melanoma.
|
|
Academic Article
|
CD56dim CD16- Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-a.
|
|
Academic Article
|
An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma.
|
|
Academic Article
|
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
|
|
Academic Article
|
CTLA-4 blockade and interferon-a induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma.
|
|
Academic Article
|
Neoadjuvant Pembrolizumab and High-Dose IFNa-2b in Resectable Regionally Advanced Melanoma.
|
|
Academic Article
|
Dysregulated NF-?B-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma.
|
|
Academic Article
|
Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males.
|
|
Academic Article
|
Interferon-alpha in tumor immunity and immunotherapy.
|
|
Academic Article
|
Patient-reported tolerability of adjuvant ipilimumab (3 or 10?mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609.
|